Cas9-mediated gene editing promises to correct DNA mutations underlying human diseases. In principle, many mutations can be individually corrected by homology-directed repair (HDR) using an exogenous DNA template. However, monogenic recessive genetic diseases typically involve many distinct mutations present across the gene. For example, more than 95 known mutations in the FAH gene can cause hereditary tyrosinemia type 1 (HT1) 1, 2 . Mutation-independent gene repair strategies that avoid the need to deliver an exogenous DNA templates would substantially simplify the development of therapies.
In compound heterozygotes, each allele of the mutant gene harbors a different genetic lesion. A sizable fraction of human autosomal recessive genetic disorders-including HT1 and lysosomal diseasesare caused by such compound heterozygous mutations 1, 3 . We hypothesized that reconstituting the correct genetic information present on both compound heterozygous mutant alleles into one allele could create a functional copy of the disease gene ( Fig. 1a) . Targeted nucleases [4] [5] [6] [7] [8] have been used to induce reciprocal translocation between non-homologous chromosomes in vitro and in vivo, aiming to study the mechanisms of chromosome translocation or model certain types of cancer. Here, we used Cas9 to create double-stranded DNA breaks cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice We report a genome-editing strategy to correct compound heterozygous mutations, a common genotype in patients with recessive genetic disorders. Adeno-associated viral vector delivery of Cas9 and guide RNA induces allelic exchange and rescues the disease phenotype in mouse models of hereditary tyrosinemia type I and mucopolysaccharidosis type I. This approach recombines non-mutated genetic information present in two heterozygous alleles into one functional allele without using donor DNA templates.
in both chromosomal homologs in a compound heterozygous mouse model of HT1, thereby inducing allelic exchange between two different mutant alleles and rescuing the disease phenotype.
HT1 is caused by loss-of-function mutations in the FAH gene, which encodes fumarylacetoacetate hydrolase (FAH), an enzyme required for tyrosine catabolism. Loss of FAH causes accumulation of toxic tyrosine metabolites in the liver and other organs. The toxicity can be relieved by oral administration of 2-(2-nitro-4trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), which blocks tyrosine catabolism at an early step, and thus prevents the formation of toxic intermediates 9 . To test our strategy, we used two HT1 mouse models that carry different mutations in the Fah gene. The Fah neo/neo mouse carries an insertion of a neomycin-resistance gene (neo) in exon 5, while the Fah PM/PM mouse carries a G-to-A transition that causes exon 8 skipping during splicing. Neither Fah mutant produces FAH protein detectable by immunohistochemistry (IHC). By crossing homozygotes of each mutation, we generated compound heterozygous Fah neo/PM mice ( Fig. 1b) .
To generate genomic DNA breaks promoting allelic exchange, newborn Fah neo/PM mice were systematically treated with a pair of liver-tropic recombinant adeno-associated virus (rAAV) vectors: one expressing Streptococcus pyogenes Cas9 (rAAV9-SpCas9) and the other producing a single guide RNA (sgRNA) targeting Fah intron 7 (scAAV8-sgFah; Supplementary Fig. 1a-c) . As a control, we replaced sgFah with an sgRNA targeting intron 2 of the Aspa gene (scAAV8-sgAspa). To allow sufficient time for genome editing to occur, mice were maintained on drinking water containing NTBC until 5 weeks old ( Fig. 1c) . We euthanized two mice from each group at 5 weeks old, and confirmed that both the Fah and Aspa sgRNAs had induced insertions or deletions (indels) at the targeted genomic sites in the liver (Supplementary Fig. 1d-f ). FAH IHC of liver tissue sections detected clusters of FAH-positive hepatocytes in the sgFah-treated mice but not the sgAspa control mice ( Fig. 1d) . Reverse-transcription PCR (RT-PCR) of total liver RNA revealed the presence of wild-type Fah mRNA spanning exon 5 to exon 9 in the sgFah but not the sgAspa control mice (Fig. 1e) .
To determine whether sufficient functional FAH protein was produced by the Cas9/sgFah-treated mice, we withdrew NTBC from a subset of treated mice 5 weeks after birth. All control mice lost >20% of body weight within 1 month after NTBC withdrawal owing to liver failure and were euthanized ( Fig. 2a) . Naive compound heterozygous mice receiving no rAAV treatment suffered similar weight loss within 1 month ( Supplementary Fig. 2) . In contrast, the sgFahtreated mice initially lost weight, but eventually achieved normal, B r i e f c o m m u n i c at i o n s stable body weight ( Fig. 2a) . FAH IHC showed that FAH-positive hepatocytes repopulated most of the liver in the sgFah-treated mice, reflecting the growth advantage of corrected hepatocytes over FAHnull cells (Fig. 2b) 9 . The FAH-positive hepatocytes were morphologically normal as assessed by hematoxylin and eosin staining (Fig. 2c) . The phenotype of three additional sgFah-treated mice was not initially rescued after NTBC withdrawal. We returned them to NTBC for 1 more week, and the phenotype showed rescue to an extent similar to that of the other rescued mice-the three mice no longer required NTBC ( Supplementary Fig. 3 ). The variation of rescue efficacy in individual mice may be due to the efficiency of FAH restoration in the liver, which ranges from 0.4% to 1.6% (median = 0.61%) and is not correlated with the Cas9 delivery efficiency (Supplementary Fig. 4 ). Whereas the control mice showed elevated serum transaminase levels, reflecting liver injury, the sgFah-treated mice had significantly lower serum transaminase levels, suggesting recovery from liver injury ( Fig. 2d) . Reverse-transcription quantitative PCR (RT-qPCR) of Fah mRNA containing exons 8 and 9 showed that mutation-free Fah gene expression was restored to 40% of normal levels in the sgFahtreated mice ( Fig. 2e) . High-throughput RNA sequencing showed a similar level of Fah mRNA with exon 8 inclusion (Fig. 2f) . The Cas9/sgFah-treatment regimen did not rescue the phenotype of mice homozygous for either mutation (Supplementary Fig. 5 ). In another set of experiments, rAAV delivery of Cas9 and sgFah in young adult compound heterozygous mice also rescued the disease phenotype ( Supplementary Fig. 6 ), suggesting that allelic exchange can occur in hepatocytes beyond the fast-proliferating, postnatal stage.
We further tested the therapeutic efficacy of allelic exchange in a compound heterozygous mouse model of mucopolysaccharidosis type I (MPS-I) ( Supplementary Fig. 7a,b) , a lysosomal disease caused by the lack of α-L-iduronidase (IDUA) and the resulting accumulation of certain types of glycosaminoglycans (GAGs). Residual IDUA activity as low as 0.2% of normal levels has been shown to attenuate the disease severity in MPS-I patients 10 . We detected allelic exchange in the heart at both the genomic DNA level (Supplementary Fig. 7c ) and the cDNA level ( Supplementary Fig. 7d ). The apparent high level of restoration of the mutation-free Idua cDNA is likely due to the nonsense-mediated mRNA decay of the Idua W392X transcript 11 . In the compound heterozygous MPS-I mice, rAAV treatment at a young adult age restored IDUA activity to ~0.5% of the wild-type level, and substantially reduced GAG accumulation in the heart ( Supplementary Fig. 7e,f) . Thus, Cas9-induced, allelic exchange has the potential for gene correction in post-mitotic tissues.
To test whether allelic exchange was the mechanism for disease correction in the compound heterozygous Fah mutant mice, we used a circularization PCR strategy to generate short amplicons containing the two original mutations; sequencing the amplicons readily differentiates between the original compound heterozygous alleles and the exchanged alleles that carry either both or neither of the original mutations ( Supplementary Fig. 8a ). We detected exchanged alleles only in the sgFah-treated mice and not in the control mice ( Fig. 2g and Supplementary Fig. 8b ). The Fah neo/PM allele detected in the sgFahtreated mice that survived NTBC withdrawal is unlikely to have been generated by gene conversion (Supplementary Fig. 9a ), because cells harboring such a Fah double-mutation allele would be lost during selection without the co-existence of a Fah functional allele. Indeed, a gene conversion experiment targeting Fah intron 9 did not restore FAH production ( Supplementary Fig. 9b-e ). Using a fluorescent reporter and a LIG4 −/− cell line, we found that LIG4 (a key enzyme in NHEJ, non-homologous end-joining) plays a role in DNA translocation in human cells (Supplementary Fig. 10 ). Although these experiments were performed with episomal plasmid DNA and in cancer cell lines, the results are consistent with previous reports that chromosomal translocation relies on an end-joining DNA repair mechanism 12, 13 .
The mice homozygous for either Fah mutation were maintained on different genetic backgrounds that harbor different tyrosinase (Tyr) alleles in linkage with Fah (see Animal use section in the Online Methods), allowing us to examine whether allelic exchange can occur between homologous chromosomes during cell division by analyzing the segregation pattern of the Tyr and Fah mutations Fig. 11a ). This analysis indicates that allelic exchange may occur between homologous chromosomes during the G2 phase, followed by X segregation during mitosis (i.e., the two exchanged alleles are segregated into different daughter cells) ( Supplementary Fig. 11b ). However, we cannot rule out that allelic exchange may also precede Z segregation (i.e., the two exchanged alleles segregate into the same daughter cell) or at the G0/G1 phase. Our allelic exchange approach has the potential to treat a large population of patients, although more rare homozygous mutations must still be corrected by HDR 14, 15 . Supplementary Figure 4 for detailed procedure). Each bar represents one mouse, either treated with ctrl rAAV and euthanized due to >20% body weight loss after NTBC withdrawal (ctrl), or treated with sgFah rAAV and euthanized after initial body weight loss was reversed (sgFah). TOPO reads indicative of different Fah alleles are color-coded. Note that the Fah neo-PM and Fah WT alleles resulting from allelic exchange were detected only in the sgFah group, but not in the ctrl group. In all dot plots, each dot represents one mouse. Horizontal lines depict the mean values. Error bars represent s.d.
B r i e f c o m m u n i c at i o n s Several advantages distinguish our Cas9/sgRNA-mediated allelic exchange from other therapeutic in vivo genome-editing approaches such as HDR. First, a single validated sgRNA suffices to correct multiple distinct mutations. Second, the sgRNA can target an intronic site, avoiding the potentially disrupting effect of out-of-frame indels in the protein-coding sequence 16 and increasing the range of potential target sites. Finally, no exogenous DNA repair template is needed. The polyploidy nature of some hepatocytes 17 may potentially enhance the exchange frequency as a result of the presence of multiple copies of homologous chromosomes and concurrent Cas9mediated cleavages.
Although the exact DNA repair mechanism involved in Cas9/ sgRNA-mediated allelic exchange is beyond the scope of this study, we postulate that it is likely the same as in general chromosomal translocation 12, 13, 18 . One limitation of our approach is that allelic exchange occurs at low frequency. For diseases such as HT1 in which corrected hepatocytes have a growth advantage allowing them to repopulate nearly the entire liver, the low frequency of allelic exchange poses no barrier to successful therapy. Such growth advantage of gene-modified cells has been recently reported for other diseases afflicting hepatocytes 19 . For diseases where genetic correction confers no growth advantage, an engineered system allowing selection of gene-modified cells could be used 20 .
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oNLINe MeThoDS Animal use. The mice homozygous for the Fah neo or Fah PM allele 21, 22 were kindly provided to us by M. Grompe, and maintained on 129 background and C57 background, respectively. The C57 background harbors the Tyr C mutation 23 that causes albinism. Mice were fed with 10 mg/L NTBC [2-(2nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione] (Sigma-Aldrich, Cat. No. PHR1731-1G) in drinking water when indicated. HT1 mice of both sexes were used in experiments. The mice homozygous for the Idua neo or Idua W392X allele 11, 24 were purchased from the Jackson Laboratory (Stock No. 004068 and 017681, respectively). Only male MPS-I mice were used in experiments. All animal procedures were reviewed and approved by The Institutional Animal Care and Use Committee (IACUC) at University of Massachusetts Medical School, and performed in compliance with all relevant ethical regulations.
Recombinant adeno-associated viral (rAAV) vectors.
The mouse U1a promoter 25 drives the expression of S. pyogenes Cas9 (SpCas9). This cassette was packaged into a single-stranded rAAV9 vector. The sgRNAs targeting the mouse Fah intron 7 (sgFah), Fah intron 9 (sgFah.Intron9), Aspa intron 2 (sgAspa), and Idua intron 9 (sgIdua) are driven by U6 promoter. The sgRNA sequences are shown in Supplementary Figure 12a . The U6-sgRNA cassette is followed by another cassette expressing enhanced green fluorescent protein (EGFP) driven by the cytomegalovirus-enhancer/chicken beta-actin promoter. These constructs were packaged into self-complementary vectors of AAV8 (scAAV8, for sgFah, sgFah.Intron9 and sgAspa) or scAAV9 (for sgIdua). rAAV vectors were produced by a triple-transfection method, purified by CsCl sedimentation and dialysis 26 . Titer of rAAV was determined by droplet digital PCR (for rAAV genome) and gel electrophoresis followed by silver staining (for rAAV capsid). Postnatal day 1 (P1) pups were injected with a mixture of rAAV-SpCas9 and scAAV-sgRNA at 1:1 ratio [4.0 × 10 11 genome copies (GCs) in total] by facial vein injection. 6-week-old mice were injected with the same mixture of rAAV vectors of 2.0 × 10 12 GCs in total by tail vein injection.
T7 endonuclease I (T7EI) assay. Tissues were powdered in liquid nitrogen, and an aliquot of tissue powder (~30 mg) was used to extract total DNA using the QIAamp DNA Mini Kit (Qiagen, Cat. No. 51306). PCR was carried out with the primers shown in Supplementary Figure 12b TOPO sequencing. Purified PCR products were cloned into a TOPO vector (Life Technologies, Cat. No. 450245) to transform DH5α Escherichia coli cells. Individual clones were expanded and subjected to plasmid extraction using QIAcube (Qiagen, Cat. No. 9001292), and Sanger sequencing using the M13F primer (Supplementary Fig. 12b ).
Histological analysis.
Mice were transcardially perfused with ice-cold PBS. Liver was dissected and fixed in 10% buffered formalin overnight. Immunohistochemistry (IHC) and hematoxylin and eosin (HE) stain were performed by the Morphology Core at University of Massachusetts Medical School using standard procedures. The FAH antibody used in IHC (Abcam, Cat. No. ab81087) was 1:400 diluted.
Reverse transcription PCR.
An aliquot of tissue powder was used to extract total RNA using the Direct-zol RNA Miniprep kit (Zymo Research, Cat. No. R2052). RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Fisher Scientific, Cat. No. 43-688-13), and subjected to PCR with primers DW871 and DW874 (Supplementary Fig. 12b ) using KOD Hot Start Master Mix (EMD Millipore, Cat. No. 71842-4). PCR products were resolved on agarose gel with ethidium bromide.
Droplet digital PCR (ddPCR).
Mouse liver genomic DNA or cDNA was used in ddPCR to quantify rAAV-SpCas9 genome copy (GC) number, SpCas9 cDNA level, and neo gene copy number. SpCas9 GC number was determined in a multiplexed reaction using a customized TaqMan reagent targeting SpCas9 (Thermo Fisher Scientific, Assay ID: AIAA0SW) and a commercial TaqMan reagent targeting Tfrc (Thermo Fisher Scientific, Cat. No. 4458367). SpCas9 cDNA was determined in a multiplexed reaction using the same SpCas9 TaqMan reagent and a TaqMan reagent targeting Gusb (Thermo Fisher Scientific, Assay ID: Mm01197698_m1). The neo gene copy number was quantified using an EvaGreen-based PCR (primers shown in Supplementary Fig. 12) , and normalized to the copy number of Tfrc. DdPCR was performed with a QX200 ddPCR system (Bio-Rad).
Serum aspartate transaminase (AST), alanine transaminase (ALT) assay.
Blood (~300 µL) was drawn from facial vein immediately before euthanasia, and serum was isolated using a serum separator (BD, Cat. No. 365967) and stored under -80 °C until assay. AST and ALT levels were determined using commercial test kits per manufacturer's instructions (TECO DIAGNOSTICS, Cat. No. A559150 and A524150).
RT-qPCR.
Liver cDNA was prepared as described above, and used for qPCR. Two separate reactions were performed for each sample. One reaction is for Fah with primers DW884 and DW885 (Supplementary Fig. 12b ) and iTaq Universal SYBR Green Supermix (Bio-Rad, Cat. No. 1725125). The other reaction is for Gapdh as normalization control using a pre-designed TaqMan reagent (Life Technologies, Cat. No. 4352339E).
Next-generation RNA sequencing (RNA-seq). Liver total RNA was extracted using the mirVana miRNA Isolation Kit (Life Technologies, Cat. No. AM1561). Ribosomal RNA (rRNA) was depleted using a mixture of 186 DNA oligos targeting mouse rRNA and RNase H (Epicentre, Cat. No. H39500). RNAseq library was prepared using a method previously described 27 , and quantified using the KAPA Library Quantification Kit (Kapa Biosystems, Cat. No. KK4873). Equal amount of library material derived from each mouse was pooled and subjected to sequencing. Next-generation sequencing was carried out using the Illumina NextSeq 500 System.
Iduronidase activity assay.
Mice were transcardially perfused with ice-cold PBS, and tissues were immediately dissected, snap-frozen in liquid nitrogen, and stored under -80 °C until assay. The iduronidase activity assay was performed using a protocol previously described 11, 28 with minor modifications. Tissues were homogenized in ice-cold T-PER protein extraction reagent (Thermo Fisher Scientific, Cat. No. 78510) with protease inhibitor (Roche, Cat. No. 4693159001) using TissueLyser II (Qiagen). Supernatant was used to quantify total protein concentration using the bicinchoninic acid (BCA) method (Pierce, Cat. No. 23225). No more than 80 µg of total protein was used in the enzymatic reaction (100 µL of total reaction volume), which includes sodium formate buffer, pH 3.5 (130 mM), d-saccharic acid 1,4-lactone monohydrate (0.42 mg/mL, Sigma-Aldrich, Cat. No. S0375), and 4MU-iduronic acid (0.12 mM, Gold Biotechnology, Cat. No. M-570-5). The reaction was incubated under 37 °C for 24-48 h, and quenched with glycine buffer, pH 10.8. The fluorescence of released 4MU (excitation wavelength: 365 nm; emission wavelength: 450 nm) was detected using a fluorescence plate reader (BioTek), and compared against a standard curve generated using 4MU (Sigma-Aldrich, Cat. No. M1381). The iduronidase specific activity was calculated as 4MU released (pmole) per milligram of total protein per hour.
Glycosaminoglycan (GAG) assay. Tissues were homogenized in a mixture of chloroform and methanol (2:1) using TissueLyser II (Qiagen), and dried in a Vacufuge (Eppendorf) to remove fat. The dried and defatted tissue was weighed, and digested using papain (Sigma-Aldrich, Cat. No. P3125) at 60 °C overnight. The supernatant was used in the Blyscan assay to quantify GAG content using chondroitin-4-sulfate as standard (Accurate Chemical, Cat. No. CLRB1000). The GAG level was calculated as GAGs (microgram) per milligram of dried, defatted tissue.
Circularization PCR. Liver total DNA (5 µg) was digested with SphI-HF (NEB, Cat. No. R3182L) and ScaI-HF (NEB, Cat. No. R3122L) for 1 hour. The resulting DNA fragments were resolved on 0.8% agarose gel, and the DNA from the 3.0-to 4.0-kbp region was excised from the gel and purified using the QIAquick Gel Extraction Kit (Qiagen, Cat. No. 28706). DNA was end-blunted using DNA polymerase I, large (Klenow) fragment (NEB, Cat. No. M0210L), and underwent self-ligation using T4 DNA ligase (NEB, Cat. No. M0202T). Ligation product was purified using the QIAquick PCR Purification Kit (Qiagen, Cat. No. 28106), and subjected to PCR with primers DW888 and DW889 (Supplementary Fig. 12b ) using KOD Hot Start Master Mix (EMD Millipore, Cat. No. 71842-4). PCR products were TOPO cloned and sequenced as mentioned above. Quantification of mutation frequency. The neo gene copy number was determined by ddPCR as described above. Normalization to Tfrc gene copy number (two copies per diploid genome) allows for the calculation of neo frequency (i.e., neo copy number/Tfrc copy number). Short amplicons spanning the Tyr C or Fah PM mutation were generated by PCR using KOD Hot Start Master Mix (EMD Millipore, Cat. No. 71842-4). Amplicons generated from individual mice were labeled by using barcoded PCR primers (Supplementary Fig. 12 ). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, Cat. No. 28106). Purified amplicons from multiple mice were pooled, and the mixture was subjected to single-molecule, real-time (SMRT) sequencing using an RSII Instrument (Pacific Biosciences), running the SMRT Analysis v2.3 software packages at the Deep Sequencing Core Facility at University of Massachusetts Medical School. Reads were demultiplexed and aligned to custom reference sequences representing the Tyr or Fah amplicons using BWA-MEM on the Galaxy web-based platform for genome data analysis [30] [31] [32] . "Mutation frequencies" at each locus were reported as the percentage of aligned reads carrying the Tyr C allele (G-to-C mutation) or the Fah PM allele (G-to-A mutation) among all reads that correctly map to the respective Tyr or Fah references, as assessed on the Integrative Genomes Viewer (IGV, version 2.3.98) 33 .
Idua amplicon sequencing. To quantify the allelic exchange frequency at the genomic DNA level, a nested PCR was used to amplify a portion of the Idua gene spanning the loxP insertion and the W392X mutation site (primers are listed in Supplementary Fig. 12) (Supplementary Fig. 7) . The bar-coded amplicons from six samples were pooled together and subjected to SMRT sequencing as described above. Amplicons that contain both the loxP insertion and the W392X mutation are derived from the original Idua W392X allele, whereas the amplicons that contain the loxP insertion but not the W392X mutation represent the exchanged mutation-free allele. To examine the restoration of mutation-free Idua mRNA, a gene-specific primer was used to reverse-transcribe Idua mRNA into cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific, Cat. No. 18080051). A nested PCR was used to amplify a portion of the Idua cDNA spanning the neo insertion in exon 7 and the W392X mutation in exon 10 (primers are listed in Supplementary Fig. 12) (Supplementary Fig. 7) . The bar-coded amplicons from six samples were pooled together and subjected to SMRT sequencing. Amplicons that contain the W392X mutation represent the cDNA expressed from the original Idua W392X allele, whereas the amplicons that contain neither the neo insertion nor the W392X mutation represent the cDNA expressed from the exchanged mutation-free allele.
Statistical analysis. Comparison between two groups were analyzed by
Student's t-test (two-sided). Comparison among three or more groups were analyzed by one-way ANOVA, followed by pair-wise comparison that was corrected for multiple comparisons. All statistical analysis was performed using Prism 7. More information about data analysis can be found in the Life Sciences Reporting Summary.
Life Sciences Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. SMRT sequencing data and RNA sequencing data can be found in the NCBI sequence read archive (SRA) under accession code SRP148742. Other data supporting the findings of this study are available within the paper, or from the corresponding authors upon reasonable request.
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Data exclusions
Describe any data exclusions.
No data are excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were randomly assigned to control or treatment group.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
A technician was blinded to the group allocation when body weight and microscopic images were taken. For other assays, samples of all groups were processed in parallel.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
